Raymond James Financial Inc. Takes Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Raymond James Financial Inc. purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 201,623 shares of the biopharmaceutical company’s stock, valued at approximately $1,722,000. Raymond James Financial Inc. owned 0.13% of Ocular Therapeutix at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in OCUL. Vanguard Group Inc. boosted its position in Ocular Therapeutix by 1.2% during the fourth quarter. Vanguard Group Inc. now owns 8,483,913 shares of the biopharmaceutical company’s stock worth $72,453,000 after purchasing an additional 99,730 shares in the last quarter. Deltec Asset Management LLC raised its holdings in shares of Ocular Therapeutix by 0.6% in the 4th quarter. Deltec Asset Management LLC now owns 2,616,373 shares of the biopharmaceutical company’s stock worth $22,344,000 after purchasing an additional 16,300 shares during the period. Artisan Partners Limited Partnership raised its stake in shares of Ocular Therapeutix by 26.4% in the 4th quarter. Artisan Partners Limited Partnership now owns 1,334,702 shares of the biopharmaceutical company’s stock valued at $11,398,000 after acquiring an additional 278,610 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in shares of Ocular Therapeutix by 1.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,131,485 shares of the biopharmaceutical company’s stock valued at $9,663,000 after buying an additional 21,025 shares during the period. Finally, Rosalind Advisors Inc. grew its stake in shares of Ocular Therapeutix by 27.5% during the fourth quarter. Rosalind Advisors Inc. now owns 1,128,700 shares of the biopharmaceutical company’s stock valued at $9,639,000 after acquiring an additional 243,700 shares in the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix Trading Up 2.8 %

Shares of NASDAQ:OCUL opened at $8.53 on Friday. Ocular Therapeutix, Inc. has a 52-week low of $4.79 and a 52-week high of $11.78. The company has a market cap of $1.36 billion, a P/E ratio of -6.46 and a beta of 1.49. The stock’s 50-day moving average is $7.36 and its 200-day moving average is $8.44. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.94 and a current ratio of 13.01.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The firm had revenue of $17.08 million for the quarter, compared to the consensus estimate of $16.89 million. Equities research analysts predict that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada started coverage on shares of Ocular Therapeutix in a research note on Tuesday, March 18th. They issued an “outperform” rating and a $17.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. William Blair began coverage on Ocular Therapeutix in a research note on Tuesday, April 8th. They set an “outperform” rating for the company. JMP Securities set a $19.00 target price on Ocular Therapeutix in a report on Tuesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, March 4th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, Ocular Therapeutix has a consensus rating of “Moderate Buy” and a consensus target price of $16.38.

Insider Activity

In other Ocular Therapeutix news, insider Pravin Dugel sold 21,475 shares of the firm’s stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This trade represents a 0.61 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Donald Notman sold 11,119 shares of Ocular Therapeutix stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total transaction of $86,839.39. Following the transaction, the insider now directly owns 193,444 shares in the company, valued at approximately $1,510,797.64. This represents a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.50% of the stock is owned by corporate insiders.

Ocular Therapeutix Profile

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.